Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Staff Scientist, The Wistar Institute 2016 - 2018
  • Post Doctoral Fellow, The Wistar Institute 2012 - 2016
  • Ph.D., University of Pennsylvania 2012
• 

  Duke Appointment History

  • Assistant Professor of Neurosurgery, Neurosurgery, Neurosurgery 2018 - 2020
  • Assistant Professor in Pathology, Pathology, Clinical Science Departments 2018 - 2020
• Research
• 

  Selected Grants

  • 6-Thio-Deoxyguanosine: A novel telomerase-mediated therapy for oligodendroglioma linking cell-intrinsic DNA damage to immune activation awarded by Oligo Nation 2021 - 2023
  • ATRX Mutations in Determining Immunity Against Glioma awarded by Brain Tumor Research Charity 2021 - 2022
• 

  External Relationships

  • General Dynamics Information Technology
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Liu, J., Rebecca, V. W., Kossenkov, A. V., Connelly, T., Liu, Q., Gutierrez, A., … Herlyn, M. (2021). Neural crest-like stem cell transcriptome analysis identifies LPAR1 in melanoma progression and therapy resistance. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-20-1496
       Full Text  Link to Item
    • Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., … Guo, W. (2021). Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene. https://doi.org/10.1038/s41388-021-01911-5
       Full Text  Link to Item
    • Liu, D., Lin, J.-R., Robitschek, E. J., Kasumova, G. G., Heyde, A., Shi, A., … Boland, G. M. (2021). Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat Med, 27(6), 985–992. https://doi.org/10.1038/s41591-021-01331-8
       Full Text  Link to Item
    • Marusak, C., Thakur, V., Li, Y., Freitas, J. T., Zmina, P. M., Thakur, V. S., … Bedogni, B. (2020). Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. Clin Cancer Res, 26(22), 6039–6050. https://doi.org/10.1158/1078-0432.CCR-19-2773
       Full Text  Link to Item
    • Lazar, I., Fabre, B., Feng, Y., Khateb, A., Turko, P., Martinez Gomez, J. M., … Ronai, Z. A. (2020). SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth. Mol Cancer Res, 18(10), 1560–1573. https://doi.org/10.1158/1541-7786.MCR-20-0291
       Full Text  Link to Item
    • Wang, L., Gao, Y., Zhang, G., Li, D., Wang, Z., Zhang, J., … Liao, X. (2020). Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade. Sci Transl Med, 12(560). https://doi.org/10.1126/scitranslmed.aax2282
       Full Text  Link to Item
    • Yu, S., & Zhang, G. (2020). EFCC1 as a putative prognostic biomarker in lung adenocarcinoma. Ann Transl Med, 8(16), 981. https://doi.org/10.21037/atm-2020-93
       Full Text  Link to Item
    • Kwon, S. M., Budhu, A., Woo, H. G., Chaisaingmongkol, J., Dang, H., Forgues, M., … Wang, X. W. (2019). Functional Genomic Complexity Defines Intratumor Heterogeneity and Tumor Aggressiveness in Liver Cancer. Scientific Reports, 9(1). https://doi.org/10.1038/s41598-019-52578-8
       Full Text
    • Aloia, A., Müllhaupt, D., Chabbert, C. D., Eberhart, T., Flückiger-Mangual, S., Vukolic, A., … Kovacs, W. J. (2019). A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. Clin Cancer Res, 25(22), 6852–6867. https://doi.org/10.1158/1078-0432.CCR-19-0253
       Full Text  Link to Item
    • Griss, J., Bauer, W., Wagner, C., Simon, M., Chen, M., Grabmeier-Pfistershammer, K., … Wagner, S. N. (2019). B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat Commun, 10(1), 4186. https://doi.org/10.1038/s41467-019-12160-2
       Full Text  Link to Item
    • Sugarman, E. T., Zhang, G., & Shay, J. W. (2019). In perspective: An update on telomere targeting in cancer. Mol Carcinog, 58(9), 1581–1588. https://doi.org/10.1002/mc.23035
       Full Text  Link to Item
    • Buj, R., Chen, C.-W., Dahl, E. S., Leon, K. E., Kuskovsky, R., Maglakelidze, N., … Aird, K. M. (2019). Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming. Cell Reports, 28(8), 1971-1980.e8. https://doi.org/10.1016/j.celrep.2019.07.084
       Full Text
    • Atay, C., Kwak, T., Lavilla-Alonso, S., Donthireddy, L., Richards, A., Moberg, V., … Gabrilovich, D. I. (2019). BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. Clin Cancer Res, 25(9), 2783–2794. https://doi.org/10.1158/1078-0432.CCR-18-2725
       Full Text  Link to Item
    • Sahu, A. D., S Lee, J., Wang, Z., Zhang, G., Iglesias-Bartolome, R., Tian, T., … Ruppin, E. (2019). Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Mol Syst Biol, 15(3), e8323. https://doi.org/10.15252/msb.20188323
       Full Text  Open Access Copy  Link to Item
    • Ojha, R., Leli, N. M., Onorati, A., Piao, S., Verginadis, I. I., Tameire, F., … Amaravadi, R. K. (2019). ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. Cancer Discov, 9(3), 396–415. https://doi.org/10.1158/2159-8290.CD-18-0348
       Full Text  Link to Item
    • Rebecca, V. W., Nicastri, M. C., Fennelly, C., Chude, C. I., Barber-Rotenberg, J. S., Ronghe, A., … Amaravadi, R. K. (2019). PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer. Cancer Discovery, 9(2), 220–229. https://doi.org/10.1158/2159-8290.cd-18-0706
       Full Text
    • Liu, S., Zhang, G., Guo, J., Chen, X., Lei, J., Ze, K., … Xu, X. (2018). Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nature Communications, 9(1). https://doi.org/10.1038/s41467-018-07126-9
       Full Text
    • Zhang, G., & Shay, J. W. (2018). Inducing rapid telomere irreparable damage in telomerase-expressing cancers. Oncotarget, 9(88), 35803–35804. https://doi.org/10.18632/oncotarget.26317
       Full Text
    • Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., … Regev, A. (2018). A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell, 175(4), 984-997.e24. https://doi.org/10.1016/j.cell.2018.09.006
       Full Text
    • Pathria, G., Scott, D. A., Feng, Y., Sang Lee, J., Fujita, Y., Zhang, G., … Ronai, Z. A. (2018). Targeting the Warburg effect via LDHA inhibition engages ATF 4 signaling for cancer cell survival. The Embo Journal, 37(20). https://doi.org/10.15252/embj.201899735
       Full Text
    • Auslander, N., Zhang, G., Lee, J. S., Frederick, D. T., Miao, B., Moll, T., … Ruppin, E. (2018). Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nature Medicine, 24(10), 1545–1549. https://doi.org/10.1038/s41591-018-0157-9
       Full Text
    • Simpkins, F., Jang, K., Yoon, H., Hew, K. E., Kim, M., Azzam, D. J., … Slingerland, J. M. (2018). Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells. Clinical Cancer Research, 24(19), 4874–4886. https://doi.org/10.1158/1078-0432.ccr-17-3697
       Full Text
    • Zhang, G., Wu, L. W., Mender, I., Barzily-Rokni, M., Hammond, M. R., Ope, O., … Shay, J. W. (2018). Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research, 24(19), 4771–4784. https://doi.org/10.1158/1078-0432.ccr-17-2773
       Full Text
    • Cañadas, I., Thummalapalli, R., Kim, J. W., Kitajima, S., Jenkins, R. W., Christensen, C. L., … Barbie, D. A. (2018). Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nature Medicine, 24(8), 1143–1150. https://doi.org/10.1038/s41591-018-0116-5
       Full Text
    • Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., … Guo, W. (2018). Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature, 560(7718), 382–386. https://doi.org/10.1038/s41586-018-0392-8
       Full Text
    • Echevarría‐Vargas, I. M., Reyes‐Uribe, P. I., Guterres, A. N., Yin, X., Kossenkov, A. V., Liu, Q., … Villanueva, J. (2018). Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma. Embo Molecular Medicine, 10(5). https://doi.org/10.15252/emmm.201708446
       Full Text
    • Al Emran, A., Marzese, D. M., Menon, D. R., Stark, M. S., Torrano, J., Hammerlindl, H., … Schaider, H. (2018). Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget, 9(9), 8206–8222. https://doi.org/10.18632/oncotarget.23654
       Full Text
    • Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., … Barbie, D. A. (2018). Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery, 8(2), 196–215. https://doi.org/10.1158/2159-8290.cd-17-0833
       Full Text
    • Somasundaram, R., Zhang, G., Fukunaga-Kalabis, M., Perego, M., Krepler, C., Xu, X., … Wagner, S. N. (2017). Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications, 8(1). https://doi.org/10.1038/s41467-017-00452-4
       Full Text
    • Krepler, C., Sproesser, K., Brafford, P., Beqiri, M., Garman, B., Xiao, M., … Herlyn, M. (2017). A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports, 21(7), 1953–1967. https://doi.org/10.1016/j.celrep.2017.10.021
       Full Text
    • Rebecca, V. W., Nicastri, M. C., McLaughlin, N., Fennelly, C., McAfee, Q., Ronghe, A., … Amaravadi, R. K. (2017). A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. Cancer Discovery, 7(11), 1266–1283. https://doi.org/10.1158/2159-8290.cd-17-0741
       Full Text
    • Lu, H., Liu, S., Zhang, G., Bin Wu, ., Zhu, Y., Frederick, D. T., … Guo, W. (2017). PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature, 550(7674), 133–136. https://doi.org/10.1038/nature24040
       Full Text
    • Zhang, Y., Kurupati, R., Liu, L., Zhou, X. Y., Zhang, G., Hudaihed, A., … Ertl, H. C. J. (2017). Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell, 32(3), 377-391.e9. https://doi.org/10.1016/j.ccell.2017.08.004
       Full Text
    • Zhang, D., Zhang, G., Hu, X., Wu, L., Feng, Y., He, S., … Zhang, L. (2017). Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Research, 77(14), 3745–3757. https://doi.org/10.1158/0008-5472.can-16-1768
       Full Text
    • Leu, J.-J., Barnoud, T., Zhang, G., Tian, T., Wei, Z., Herlyn, M., … George, D. L. (2017). Inhibition of stress-inducible HSP70 impairs mitochondrial proteostasis and function. Oncotarget, 8(28), 45656–45669. https://doi.org/10.18632/oncotarget.17321
       Full Text
    • Vitiello, M., Tuccoli, A., D’Aurizio, R., Sarti, S., Giannecchini, L., Lubrano, S., … Poliseno, L. (2017). Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget, 8(15), 25395–25417. https://doi.org/10.18632/oncotarget.15915
       Full Text
    • Shannan, B., Watters, A., Chen, Q., Mollin, S., Dörr, M., Meggers, E., … Vultur, A. (2016). PIM kinases as therapeutic targets against advanced melanoma. Oncotarget, 7(34), 54897–54912. https://doi.org/10.18632/oncotarget.10703
       Full Text
    • Wu, L. W., Zhang, G., & Herlyn, M. (2016). Mitochondrial biogenesis meets chemoresistance in BRAF-mutant melanoma. Molecular & Cellular Oncology, 3(4), e1179381–e1179381. https://doi.org/10.1080/23723556.2016.1179381
       Full Text
    • Wu, L. W., Zhang, G., & Herlyn, M. (2016). Repurposing an HIV drug to improve efficacy of targeted therapy in melanoma. Translational Cancer Research, 5(S1), S106–S108. https://doi.org/10.21037/tcr.2016.05.28
       Full Text
    • Lu, H., Liu, S., Zhang, G., Kwong, L. N., Zhu, Y., Miller, J. P., … Guo, W. (2016). Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Reports, 15(9), 2012–2024. https://doi.org/10.1016/j.celrep.2016.04.073
       Full Text
    • Zhang, G., Frederick, D. T., Wu, L., Wei, Z., Krepler, C., Srinivasan, S., … Herlyn, M. (2016). Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. Journal of Clinical Investigation, 126(5), 1834–1856. https://doi.org/10.1172/jci82661
       Full Text
    • Hew, K. E., Miller, P. C., El-Ashry, D., Sun, J., Besser, A. H., Ince, T. A., … Simpkins, F. (2016). MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 22(4), 935–947. https://doi.org/10.1158/1078-0432.ccr-15-0534
       Full Text
    • Ravindran Menon, D., Das, S., Krepler, C., Vultur, A., Rinner, B., Schauer, S., … Schaider, H. (2015). A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene, 34(34), 4448–4459. https://doi.org/10.1038/onc.2014.372
       Full Text
    • Liu, S., Tetzlaff, M. T., Wang, T., Yang, R., Xie, L., Zhang, G., … Xu, X. (2015). miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. Pigment Cell & Melanoma Research, 28(4), 431–441. https://doi.org/10.1111/pcmr.12379
       Full Text
    • Wang, T., Xiao, M., Ge, Y., Krepler, C., Belser, E., Lopez-Coral, A., … Kaufman, R. E. (2015). BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clin Cancer Res, 21(7), 1652–1664. https://doi.org/10.1158/1078-0432.CCR-14-1554
       Full Text  Link to Item
    • Webster, M. R., Xu, M., Kinzler, K. A., Kaur, A., Appleton, J., O’Connell, M. P., … Weeraratna, A. T. (2015). Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell & Melanoma Research, 28(2), 184–195. https://doi.org/10.1111/pcmr.12330
       Full Text
    • Kraya, A. A., Piao, S., Xu, X., Zhang, G., Herlyn, M., Gimotty, P., … Speicher, D. W. (2015). Identification of secreted proteins that reflect autophagy dynamics within tumor cells. Autophagy, 11(1), 60–74. https://doi.org/10.4161/15548627.2014.984273
       Full Text
    • Zhang, G., & Herlyn, M. (2014). Linking SOX10 to a slow-growth resistance phenotype. Cell Research, 24(8), 906–907. https://doi.org/10.1038/cr.2014.67
       Full Text
    • Ma, X.-H., Piao, S.-F., Dey, S., Mcafee, Q., Karakousis, G., Villanueva, J., … Amaravadi, R. K. (2014). Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma. Journal of Clinical Investigation, 124(3), 1406–1417. https://doi.org/10.1172/jci70454
       Full Text
    • Rasanen, K., Sriswasdi, S., Valiga, A., Tang, H.-Y., Zhang, G., Perego, M., … Herlyn, M. (2013). Comparative Secretome Analysis of Epithelial and Mesenchymal Subpopulations of Head and Neck Squamous Cell Carcinoma Identifies S100A4 as a Potential Therapeutic Target. Molecular & Cellular Proteomics, 12(12), 3778–3792. https://doi.org/10.1074/mcp.m113.029587
       Full Text
    • Yang, Y., Wu, J., Demir, A., Castillo-Martin, M., Melamed, R. D., Zhang, G., … Celebi, J. T. (2013). GAB2 induces tumor angiogenesis in NRAS-driven melanoma. Oncogene, 32(31), 3627–3637. https://doi.org/10.1038/onc.2012.367
       Full Text
    • Aird, K. M., Zhang, G., Li, H., Tu, Z., Bitler, B. G., Garipov, A., … Zhang, R. (2013). Suppression of Nucleotide Metabolism Underlies the Establishment and Maintenance of Oncogene-Induced Senescence. Cell Reports, 3(4), 1252–1265. https://doi.org/10.1016/j.celrep.2013.03.004
       Full Text
    • Balaburski, G. M., Leu, J.-J., Beeharry, N., Hayik, S., Andrake, M. D., Zhang, G., … Murphy, M. E. (2013). A Modified HSP70 Inhibitor Shows Broad Activity as an Anticancer Agent. Molecular Cancer Research, 11(3), 219–229. https://doi.org/10.1158/1541-7786.mcr-12-0547-t
       Full Text
    • Zhang, G., & Herlyn, M. (2012). Human Nevi: No Longer Precursors of Melanomas? Journal of Investigative Dermatology, 132(9), 2133–2134. https://doi.org/10.1038/jid.2012.183
       Full Text
    • Ge, Y., Azuma, R., Gekonge, B., Lopez-Coral, A., Xiao, M., Zhang, G., … Kaufman, R. E. (2012). Induction of metallothionein expression during monocyte to melanoma-associated macrophage differentiation. Frontiers in Biology, 7(4), 359–367. https://doi.org/10.1007/s11515-012-1237-8
       Full Text
    • Wang, T., Ge, Y., Xiao, M., Lopez-Coral, A., Azuma, R., Somasundaram, R., … Kaufman, R. E. (2012). Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigment Cell Melanoma Res, 25(4), 493–505. https://doi.org/10.1111/j.1755-148X.2012.01005.x
       Full Text  Link to Item
    • Kumar, S. M., Zhang, G., Bastian, B. C., Arcasoy, M. O., Karande, P., Pushparajan, A., … Xu, X. (2012). Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene, 31(13), 1649–1660. https://doi.org/10.1038/onc.2011.366
       Full Text  Link to Item
    • Basu, D., Nguyen, T.-T., Montone, K. T., Zhang, G., Wang, L.-P., Diehl, J. A., … Herlyn, M. (2010). Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene, 29(29), 4170–4182. https://doi.org/10.1038/onc.2010.170
       Full Text
    • Pytel, D., Gao, Y., Mackiewicz, K., Katlinskaya, Y. V., Staschke, K. A., Paredes, M. C. G., … Diehl, J. A. (n.d.). PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma. Plos Genetics, 12(12), e1006518–e1006518. https://doi.org/10.1371/journal.pgen.1006518
       Full Text
    • Xiang, J., Zhou, L., Zhuang, Y., Zhang, J., Sun, Y., Li, S., … He, Y. (n.d.). Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by si‑STAB1 in ovarian cancer. Oncology Reports. https://doi.org/10.3892/or.2018.6658
       Full Text

  • Book Sections

    • Wu, L. W., Zhang, G., & Herlyn, M. (2017). Tumor Microenvironment for Melanoma Cells. In Melanoma Development Molecular Biology, Genetics and Clinical Application. Springer.
       Link to Item
    • Zhang, G., & Herlyn, M. (2011). Tumor Microenvironment for Melanoma Cells. In Melanoma Development Molecular Biology, Genetics and Clinical Application. Springer Science & Business Media.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.